|
|
Conference:
Pre-conference workshop
28 April 9am - 5pm
Day 1
29 April 8.30am - 5:30pm
Day 2
30 April 8.30am - 5:30pm
Post-conference workshop
1 May 9am - 5pm
Main venue: Radisson SAS Portman Hotel, London, United Kingdom
› Email a colleague
› Add this to my calendar
|
Dr Carole Longson
Health Technology Evaluation Director
NICE, UK
Dr Martin van der Graaf
Secretary Reimbursement Committee
CVZ, Netherlands
Dr Brien Benoit
Chairman
Patented Medicine Prices Review Board
Professor Silvio Garattini
Founder
Mario Negri Institute, Italy
Plus representation from:
HAS, BlueCross BlueShield, GBA, Johnson & Johnson, Serono, Baxter.
|
|
|
|
Meet our speakers
Professor Fernando Antonanzas, Professor of Applied Economics,
University of Rioja
Fernando Antoñanzas (PhD Economics Univ. Autónoma of Madrid 1983, Master of Arts, The University of Chicago 1985) is professor of Applied Economics at the University of La Rioja and was research director of SOIKOS (research institute on health economics located at Barcelona). He has been professor in other universities such as Alicante, Madrid and Zaragose. He has participated in several post-graduate programmes of different universities related to Health Economics.
His research activities have been in quantitative economics applied to health sector. He has been coauthor of several books; he is member of three editorial committees of different journals, and has published many papers on economic evaluation of health technologies. He has also participated in 6 EU funded projects during the last 7 years.
He was president of the Spanish Health Economics Association for two years during the nineties.
|
|
Executive Director,
BlueCross BlueShield
Dr. Aronson is the Executive Director of the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). She has overseen TEC's development as a nationally recognized technology assessment program and an Evidence-based Practice Center (EPC) of the Agency for Healthcare Research and Quality (AHRQ). Dr. Aronson has directed over 300 technology assessments and 10 evidence reports for AHRQ. She has published articles in Annals of Internal Medicine, Journal of the National Cancer Institute, Cancer, Journal of the American College of Surgeons, Academic Radiology, Journal of Family Practice, and Gastrointestinal Endoscopy. She represented the private sector on a U.S. Agency for International Development team providing technical assistance to the Hungarian government on building evidence-based medicine capacity in the national health insurance system. She is a member of the Institute of Medicine Forum on Drug Discovery Translation and Development, and the Steering Committee of the Chicago-Area DEcIDE Research Center and the National Business Group on Health Committee on Evidence-Based Benefit Design. Previously, Dr. Aronson was a member of Northwestern University faculty, specializing in sociology of science and medicine. She was also a post-doctoral fellow in the Science, Technology and Society Program at the Massachusetts Institute of Technology and received research awards from the National Science Foundation and the American Council of Learned Societies. Dr. Aronson's academic research focused on how the organization of scientific specialties in biomedical and clinical research affects the process of scientific discovery.
|
|
Head of the Research Department of Standardization, Licensing and Accreditation,
Moscow Medical Academy
Since 1992 Professor Avxentieva has been working for the Moscow Medical Academy named after Sechenov. She is Professor at the Training Course in Standardization in Health Care, Head of the Medical Care Quality Management and Evidence-based Medicine Research . She specialises in:
• evidence-based medicine, pharmacoeconomics, medical care quality management
• development of clinical protocols (guidelines) and medical standards
• clinico-economical (pharmacoeconomical) studies (head of the project, senior consultant)
• health technology assessment (analysis of evidence for standards and formularies)
|
|
Chairperson,
Patented Medicine Prices Review Board, Canada
Dr. Brien G. Benoit was first appointed Member of the PMPRB in May 2005. In October of the same year, Dr. Benoit became Vice-Chairperson and took on the responsibilities as Chairperson until his appointment as Chairperson in June 2006.
A Neurosurgeon, Dr. Benoit is on the Active Attending Staff of The Ottawa Hospital. Dr. Benoit is also a Professor of Neurosurgery at the University of Ottawa. Throughout his career, Dr. Benoit has held several administrative positions including Chief of Staff of the Ottawa Civic Hospital, from 1996 to 1998; Program Director, Neurosurgery at the University of Ottawa, from 1995 to 2003; Chair of Neurosurgery at the University of Ottawa, from 1997-2003; and Deputy Surgeon-in-Chief at the Ottawa Hospital (Civic Campus) from 2002 to 2004. He was also Chair of the Operating Room Committee at the Ottawa Hospital (Civic Campus), from 1993 to 2004.
Dr. Benoit has published extensively in leading academic journals. He has received several awards, including Best Surgical Teacher from the Department of Surgery of the University of Ottawa in 1991 and 2000.
In addition to being a Fellow of the Royal College of Surgeons (Neurosurgery),
Dr. Benoit is a member of several professional associations including the Canadian Medical Association, the Ontario Medical Association, the Royal College of Physicians and Surgeons of Canada, and the American College of Surgeons, to name a few.
|
|
Lindsay Chair in Health Policy & Economic Evaluations, Department of Public Health,
University of Glasgow, United Kingdom
Andrew has a DPhil in Health Economics and a MSc in Applied Statistics, both from the University of Oxford (Nuffield College). He advises on health economics research projects; his particular interests are in probabilistic modelling, clinical trials, prognostic indices and risk analysis. Andrew has worked in many disease areas including respiratory, cardiovascular, neoplasms and gastrointestinal diseases. He currently holds the Lindsay Chair in Health Policy and Economic Evaluation at the University of Glasgow, and has acted as advisor to the UK Department of Health, the UK National Institute of Clinical Excellence and a number of Pharmaceutical Companies. He also oversees the training component of Oxford Outcomes' activities.
|
|
Director, Market Access Solutions,
Bridgehead International, United Kingdom
Jim Furniss is Director, Market Access Solutions at Bridgehead International. He has a detailed understanding of pharmaceutical policy, pricing and market access issues throughout Europe and North America and extensive practical experience of Company-Government relations in drug pricing and reimbursement.
Prior to moving into consultancy Jim was head of the Pharmaceutical Industry Branch in the UK Department of Health from 1991 to 1997. In this position, he was responsible for the operation of the UK Pharmaceutical Price Regulation Scheme and for the NHS drug budget for the UK. During this time he also represented the UK on pharmaceutical issues at the European Commission. He gained valuable experience in pharmaceutical price regulation across Europe as a member of the European Commission’s Pharmaceutical Pricing Transparency Committee. He also worked with Senator Pryor and the US General Accounting Office on international drug pricing issues.
Jim has spent more than 10 years in consultancy in the pharmaceutical industry, initially with Cambridge Pharma Consultancy and most recently with Bridgehead International. During this time he has worked for a large number of pharmaceutical pricing, reimbursement and market access projects, covering all major therapy areas. His work has been primarily focused on market access for new products in European and North American markets, and the development of payer value propositions and payer-focused market access strategies; but he has also worked on medical devices and diagnostics, and on the implications for pharmaceutical companies of broader healthcare policy development. He has worked with all the major international pharmaceutical companies and many smaller companies. He is a regular speaker at international conferences on pharmaceutical pricing, reimbursement and market access issues.
|
|
Chairman,
Ethical Medicines Industry Group, United Kingdom
Leslie was appointed EMIG Chairman in 2005 and has been instrumental in the growth of EMIG from a networking group to the influential trade association it is today.
Leslie has over 20 years experience of large pharma but gained significant international business experience in the medical device industry with small and large companies. He returned to the pharma industry at a time when acquisitions were creating a gulf between 'mega' pharma and SMEs.
Leslie was CEO at Ashbourne Pharmaceuticals for seven years, changing the business model twice during that time before the business was itself, acquired.
|
|
Professor Silvio Garattini, Founder,
Mario Negri Institute, Italy
Professor Garattini was founder in 1963 and director of the Mario Negri Institute for Pharmacological Research. The Institute has now four locations (Milan, Bergamo, Ranica (Bg), S. Maria Imbaro (Ch)) and more than 850 people. He is a member of the Gruppo 2003 (a group of the most cited Italian scientists in international scientific literature). Garattini's publications in Italian and in English in international scientific journals, and texts on pharmacology, run into the hundreds. Founder of the European Organisation for Research and Treatment of Cancer (EORTC). During the last ten years professor Garattini has been a member of various organizations, among which: the Italian National Research Council (CNR) - Committee on Biology and Medicine; the National Health Council, the Committee for Italian Research Policy, set up by the Presidency of the Council of Ministers; the Commissione Unica del Farmaco (CUF) of the Ministry of Health. He was President of the European Society of Biochemical Pharmacology; member of the Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medicinal Products (EMEA), Member of the CEPR (Committee of Experts of Research Policy) at the Ministry for University and Scientific and Technological
Research; Member Scientific Committee of the Lega Italiana per la Lotta Contro i Tumori; member of the Board of the Istituto Superiore di Sanità.
|
|
Senior Research Scientist,
UBC, United Kingdom
Asha Hareendran, PhD, MA is a Senior Research Scientist for United BioSource Corporation in London, UK. She has extensive knowledge in research design and methodology in the area of health outcomes and has over 15 years of experience in the health care industry.
Dr. Hareendran’s responsibilities include instrument development and validation and the design and management of research studies focused on patient-reported outcomes (PROs). She has worked in a variety of disease areas, including coronary artery disease, venous leg ulcers, benign prostatic hypertrophy, COPD, Asthma and restless leg syndrome, among others. In addition, Dr. Hareendran has experience with the use of electronic PROs and the incorporation of translations into clinical trials. Prior to joining UBC, Dr. Hareendran was the Senior Director of Global Outcomes Research at Pfizer, Ltd. in Sandwich, UK.
She received her doctorate from the Post Graduate Institute of Medical Education & Research in Chandigarh, India and her masters of philosophy in clinical social work from the National Institute of Mental Health and Neurosciences in Bangalore, India. She also has a master’s degree in clinical medical and psychiatric social work from the Tata Institute of Social Sciencies, Bombay, India and a bachelor’s degree in Psychology from the University of Kerala, Trivandrum, India.
|
|
Director,
Oxford Outcomes Ltd, United Kingdom
Neil joined Oxford Outcomes in February 2007 as a full time Director of Health Economics following five years as a Research Fellow at the Centre for Health Economics at the University of York, where he will retain an academic affiliation. Neil has also worked extensively as an independent consultant in health economics during this time following five years as a statistician and health economist with Amgen, working in clinical development. His specialisations include the use of Bayesian evidence synthesis techniques in health technology assessment, individual patient variation in assessing the cost-effectiveness of treatment sequences for chronic diseases and value of information analysis in development portfolio management. Neil has an MSc in applied statistics and extensive experience of the use of statistical analysis to inform decision analytic-modelling. Neil has lectured on Bayesian evidence synthesis and indirect comparisons in the University of York Graduate School and York Centre for Health Economics Advanced Methods courses. He is regularly invited to present workshops to industry and at ISPOR. Neil has implemented both parametric and non-parametric survival analysis in STATA, SAS, and R and developed a number of decision-analytic models based on underlying survival analysis. He has extensive experience of Bayesian evidence synthesis techniques including: fixed and random effects modelling; mixed treatment comparisons; correlated endpoints, taking account of both within and between study correlations; and binary, linear and ordinal data. Neil is currently working on a project using binary data adjusted for length of follow-up assuming underlying survival distributions.
|
|
Executive Officer,
LFN, Sweden
Swedish pharmacist working as team leader for the medical investigators at the governmental authority, the Dental and Pharmaceuticals Benefits Agency, in Sweden. (Previously the LFN. Since October 2002 the TLV is responsible for making decisions on reimbursement status and price for pharmaceuticals in Sweden. The medical investigators main duties are handling of incoming applications for price and reimbursement on new drugs and leading projects within the national review of older reimbursed drugs. Preparing an application for decision of the Board includes contacts with the applying companies, investigational work about specific products or therapy areas, writing a memorandum and presenting the application for the Board or the Director General. The project leadership for a review includes lots of investigational work, contacts with an external group of clinical experts and contacts with all involved pharmaceutical companies.
|
|
Technical Director,
Evidence Research Unit, United Kingdom
A graduate of the University of London, with a postgraduate Diploma in Clinical Pharmacology from the University of Madrid, Ian has been working in the pharmaceutical industry for over 30 years. His main areas of expertise lie in clinical and outcomes research, and application of this experience to strategic marketing and market access. After a research career in clinical pharmacology and biostatistics, mostly in Germany, Ian moved into a project direction role in medical communications and education in New Zealand, before moving back into research to establish Mapi Values in the UK. Here, Ian specialised in clinical and humanistic outcomes for clinical development programmes and had broad involvement in the growth of the science of quality of life.
In his current position as Technical Director for the Evidence Research Unit, Ian uses his knowledge of European health policy to advise on the most appropriate strategies for drug development and marketing programmes to facilitate market access and maximize product adoption. Ian’s experience in medical communication and strategic marketing is applied to most projects, working closely with the Evidence Research Unit team to ensure consistency of approach, and delivery of technical excellence.
|
|
Director, PRO Group,
Oxford Outcomes, United Kingdom
Andrew joined Oxford Outcomes Limited in the Summer of 2007 as a Director of the PRO group. He has a background in cognitive and health psychology. Prior to joining Oxford Outcomes, Andrew was a Research Scientist and Deputy Director at United BioSource Corporation in London. His main research interests are in the assessment of health-related quality of life and medical decision making; he has also been interested in patients' perception of risk related to treatment alternatives. Andrew has undertaken work in a broad range of therapeutic areas including oncology, diabetes, asthma and vascular disease. These projects have included assessments of quality of life and cognitive function; surveys of patients' decision making and audits of practice innovations; utility estimation (through standard gamble, time trade-off, visual analogue scale and multi-attribute utility measures); determination of patient preferences through discrete choice experiments; conjoint analysis and willingness to pay; and development and validation of novel patient reported outcomes
|
|
Health Technology Evaluation Director,
NICE, United Kingdom
Carole Longson graduated with a degree and PhD in Pharmacology from the University of Aston. She then spent 8 years at Glaxo Wellcome Research and Development, working on the development of novel pharmaceuticals for hypertension, migraine, and schizophrenia. She has also undertaken a number of academic secondments including research at The Institute of Molecular Biology in Geneva, and the University of California in Irvine, USA. Carole has previously been involved in health technology assessment as Director of the Evidence Research Unit, CMC. Her research interests lie in the methodology of systematic reviews and health technology assessment.
|
|
Directeur de l'évaluation médicale, économique et de santé publique,
HAS, France
|
|
Vice President, Pricing & Reimbursement,
RTI Health Solutions, Canada
Mr. Palmer is responsible for leading RTI Health Solutions’ (RTI-HS) global pricing & reimbursement practice. He was co-founder of Palmer D’Angelo Consulting Inc (PDCI), a leading pharmaceutical pricing and reimbursement (P&R) consultancy established in 1996 and acquired by RTI International in December 2006. The firm has long been recognized for its extensive knowledge and experience assisting clients with pharmaceutical price regulation, reimbursement strategies & submissions, global pricing strategies and pharmaceutical policy and economic research projects. Before founding PDCI, Mr. Palmer was a senior official with the Canadian Patented Medicine Prices Review Board (PMPRB) in Ottawa. Prior to the PMPRB he worked with the Health Division of Statistics Canada and the Kellogg Centre for Advanced Studies in Primary Care in Montreal. A graduate of the University of Western Ontario, he has written extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at pharmaceutical congresses in Europe, the United States and Canada.
|
|
Vice President, Corporate Health Policy & Government Relations,
Merck Serono, Switzerland
In 1992, he moved into healthcare and worked for The Ares-Serono Group as Head of the Institutional Affairs Department in charge of the Rome and Brussels offices. From 1995 to 1999, he was Public Affairs Director at Baxter Healthcare, part of the European Public Affairs team. In 1999, he returned to Serono International, as Vice President Corporate Health Policy & Government Relations. He is currently member of the European Medicines Agency (EMEA) Committee for Orphan Medicinal Products Working Group with Interested Parties (COMP/WGIP). He represents Serono in the following trade associations:
EUROPABIO Vice Chairman, Board of Management, Chair of the Healthcare Council
HTAi Health Technology Assessment International Society Policy Forum
EFPIA Economic and Social Policy Committee
INTERPHARMA Economic and Policy Issues Committee.
He sits on the Board of the Foundation of the European Platform for Patients Organizations, Science & Industry (EPPOSI) and is a member of the Editorial Board of the Journal of Commercial Biotechnology.
|
|
Principal Consultant,
Bridgehead International, United Kingdom
Sasha Richardson joined Bridgehead as a Principal Consultant from Janssen-Cilag GmbH (Johnson & Johnson) where she worked as Commercial Affairs & Trade Manager in Germany. Sasha has over 11 years operational and management experience in the healthcare / life sciences sector, having gained valuable international exposure in Canada (private & public), USA (private & life sciences), UK (St. George’s Hospital), France (consumer) and Germany (pharmaceutical).
Sasha holds degrees in Biopsychology/Neurophysiology from the University of British Columbia and Physiotherapy from the University of Western Ontario. She also has an MBA from HEC Paris / London Business School, with a concentration in finance and entrepreneurship.
Sasha brings expertise in disease management, health economics, market research, cost-benefit, pricing & reimbursement, and competitor analysis of pharmaceutical drugs, medical device ventures and healthcare services gained from:
• Janssen Cilag (J&J Germany)
• Independent Healthcare Consultant (global markets)
• Working in all the major disease states covering >50 indications
• P&R Europe & US master class lecturer
As the Director of a multi-disciplined medical practice for 6 ½ years in New York, Sasha established best patient practices and reimbursement and billing practices and contract negotiations. In addition, cost effectiveness of various medical treatments was done to meet with Payers (private insurance companies/Medicare) guidelines via in depth knowledge of CPT and ICD 9 codes (reimbursement and diagnostic codes) and established clinic-payer relationships.
|
|
Director, Government Affairs and Public Policy - Europe,
Baxter World Trade SA, Belgium
Anne-Toni Rodgers is the European Director of Government Affairs and Public Policy (GAPP) for Baxter. Prior to joining Baxter Anne-Toni was a founding Director of the National Institute for Clinical Excellence and previously spent 18 years in a variety of roles for the pharmaceutical industry including, pure research, regulatory affairs, sales & marketing, and government & industry affairs.
|
|
Director, Health Economics,
Oxford Outcomes, United Kingdom
Mark Sculpher is Professor of Health Economics at the Centre for Health Economics, University of York, and is Director of the Programme on Economic Evaluation and Health Technology Assessment. He has been based at York University since 1997. Mark has worked in economic evaluations of range of technologies including angina and inguinal hernia; lasers; screening programmes for diabetic retinopathy and antenatal HIV infection; and drug treatments for dyspepsia, asthma, menorrhagia, heart disease and various cancers. He has also contributed to methods in the field, in particular relating to decision analytic modelling and handling uncertainty. He has over 100 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the Economic Evaluation of Health Care Programmes (OUP, 2005 with Drummond, Torrance, O’Brien and Stoddart) and Decision Modelling for Health Economic Evaluation (OUP, 2005 with Briggs and Claxton). He also leads the economic component of York's contribution to technology assessment reviews for the National Institute for Health and Clinical Excellence (NICE). Mark is a member of the NICE Technology Appraisal Committee and the NICE Public Health Interventions Advisory Committee, and he chaired NICE's Task Group on methods guidance for economic evaluation. He is also a member of the Commissioning Board for the NHS Health Technology Assessment programme. These services are provided by Mark acting in his capacity as a Director Of Oxford Outcomes Ltd. Although he is otherwise employed by the University of York, Mark is not acting for or representing the University in any way.
|
|
Programme Officer, Pharmaceuticals Division,
GBA, Germany
Dr Regina Skavron graduated from the Medical School of the University of Cologne, Germany, with an MD and a PhD in internal medicine. She developed her interest in health policy during a fellowship with the World Health Organisation’s Regional Office for Europe in Copenhagen, Denmark. This was followed by an MSc in Health Policy, Planning and Financing at the London School of Economics and the London School of Hygiene & Tropical Medicine. Her master’s thesis on the reference price schemes in Germany was awarded the 2007 Brian Abel-Smith Prize.
She has since been a programme officer with Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss). Her principal responsibilities within the organisation’s Pharmaceuticals Department include accompanying the introduction of cost-effectiveness analyses and the novel co-signing procedure for “special” pharmaceuticals.
|
|
Senior Consultant,
Bridgehead International, United Kingdom
Bob joined Bridgehead as a Senior Consultant from Bespak, the medical device manufacturer, where he worked in the UK commercial group before moving to manage commercial operations in the USA. During his four years with Bespak he had key account and business development responsibilities. Prior to Bespak, Bob spent 14 years with 3M. Whilst working for 3M Pharmaceuticals Bob worked in sales, clinical research and managed the UK clinical liaison/medical information group. Whilst working for 3M Drug Delivery Systems as a programme manager Bob was responsible for customer funded development/manufacturing projects.
Bob also has laboratory-based experience in microbiology and immunology working for Oxoid and the Medical Research Council.
Bob gained his first degree in Pharmacology from Leeds University, holds a Post Graduate Diploma in Clinical Research from Cardiff University and received his MBA from Warwick Business School.
Since joining Bridgehead International in February 2006 Bob has led and managed a variety of projects in a broad range of therapy areas for both the Market Access and the Technical/Commercial evaluation groups.
|
|
Senior Executive Director, Europe & Senior Scientist,
UBC
Mr. Thwaites brings extensive experience in health outcomes research, database analysis and scientific and strategic planning to UBC. Along with his operational and leadership skills, this experience further strengthens UBC’s management team and its ability to provide comprehensive strategic solutions to our clients.
Having spent many years with GlaxoSmithKline leading their Research & Development team for in-licensing and housing patient databases, their initiatives in Europe to encourage the development of electronic medical records for future medical research, and their Global Health Outcomes department, Mr. Thwaites understands the client’s perspective and needs in building a product’s value story. His experience as a management consultant with McKinsey & Co. and as an industry economist adds to his overall understanding of the health care industry from a global perspective.
Mr. Thwaites received his Master’s degree in economics from the University of Cambridge and his Master’s of Commerce degree from the University of New South Wales.
|
|
Dr Martin van der Graaff, Secretary, Reimbursement Committee,
CVZ
Dr Graaff spent 4 years in administration form development in Organon, and 7 years in pharmacokinetics and preclinical development at Solvay. He then made the switch from R&D to policy development and moved to Nefarma, the Dutch Association of the Pharmaceutical Industry. He has acted both as a regulatory expert (6 years) and a biotech and innovation expert (6 years). He joined the Dutch Healthcare Reimbursement Authority (CVZ), in 2008 in his current position.
|
|
Manager, Health Economics,
Johnson & Johnson, Belgium
|
|
|
|
|
|
|
Reserve an exhibition stand at Pharma Pricing & Market Access Outlook 2009 - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
James Hopkins on +44 (0) 207 608 7038
|
|
|
|
|
|
